Alynni (alectrnib)

Alynni (alectrnib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).56Capsules/bottle, 150 mg/Capsules, 600 mg orally twice daily with food.